Meredith Ervine is a corporate attorney focusing her practice on securities and corporate governance matters. Over the course of her career, she has worked on more than 65 securities offerings involving more than $11.3 billion. She has experience representing clients across many industries on securities issues, mergers and acquisitions, and general corporate matters, focusing primarily on public and pre-IPO companies.

  • Advises clients regarding compliance with the securities laws, including the reporting requirements of the SEC and the national securities exchanges
  • Assists clients in connection with annual and special stockholder meetings, including preparation of proxy statements
  • Counsels clients in public and private offerings of both debt and equity securities
  • Advises clients on corporate governance best practices
  • Counsels clients on transactional matters, including corporate finance and mergers and acquisitions
  • Assists clients with general contract and planning matters



Representative Matters

Representative Clients

  • Represents a Midwest-based medical device company listed on Nasdaq
  • Represents a Midwest-based clinical-stage biopharmaceutical company listed on Nasdaq
  • Represents a Midwest-based, development stage medical device company on the OTC Pink Sheets
  • Represents a retail chain specializing in home décor products headquartered in Texas and listed on the NYSE
  • Serves as secondary counsel to a media and entertainment company that is headquartered in Connecticut and listed on the NYSE
  • Serves as special or secondary counsel to three Northeast-based unaffiliated controlled companies (wholesale/retail fashion, wholesale/retail consumer goods, and manufacturer of advanced materials) listed on the NYSE
  • Advised a Northeast-based plastic packaging films manufacturer listed on Nasdaq

Recent Transactions

  • $145 million sale of electronics division of NYSE-listed company to a buyer headquartered in Japan
  • Reverse merger of a development-stage medical device company into the wholly-owned subsidiary of an OTC Pink Sheets reporting company
  • Public offering of Class A and Class B Units for a Nasdaq-listed medical device company
  • PIPE transaction of common stock and warrants for a Nasdaq-listed clinical stage biopharmaceutical company
  • Establishment of a $50 million at-the-market equity program for a Nasdaq-listed biopharmaceutical company
  • Co-lead counsel on $785 million sale of plastic packaging films manufacturer (Nasdaq) through merger to an NYSE-listed company
  • $65 million common stock rights offering and backstop commitment (NYSE) for leading contemporary fashion brand (represented the independent directors)
  • $30 million initial public offering of common stock (Nasdaq) for a clinical-stage biopharmaceutical company
  • Registered direct offerings of preferred stock and warrants for a Nasdaq-listed medical device company

Prior Experience

  • Pillsbury Winthrop Shaw Pittman LLP, Senior Associate, 2008-2015






Michigan Super Lawyers, Recognized as a Rising Star, 2019

The Best Lawyers in America

  •  Recognized in the practice areas of:
    • Corporate Governance Law, 2023
    • Securities/Capital Markets Law, 2023

Professional & Community Involvement

American Bar Association

  • Business Law, Member

State Bar of Michigan

Association for Corporate Growth Western Michigan

  • Women in Finance Committee, Member

Grand Rapids Ballet

  • Board Member, 2017
  • Development Committee Member, 2017

News & Insights


Jump to Page

By using this site, you agree to our Privacy Policy and our Disclaimer.